ArticleRespiratory research2025
Pilot study of
Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- FAPI Dimerization for Theranostic Applications: Molecular Design, Preclinical Validation, and Clinical Translation.Chemical & biomedical imaging · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
background18F-FAPI-RGD PET/CT is a dual-target tracer imaging technique that holds promise for identifying pulmonary lesions in connective tissue disease-associated interstitial lung disease (CTD-ILD) patients. Currently, clinical studies investigating 18F-FAPI-RGD PET/CT for CTD-ILD diagnosis are lacking.
methodsIn this prospective study, CTD-ILD patients from the multidisciplinary clinic of Sichuan Provincial People’s Hospital were enrolled. General clinical data and laboratory parameters were collected. All participants underwent multidisciplinary ILD diagnostic evaluation and completed 18F-FAPI-RGD PET/CT examinations to assess its clinical value in CTD-ILD diagnosis.
resultsThe study ultimately included 52 patients (35 CTD-ILD, 17 CTD). CTD-ILD patients showed significantly elevated serum IL-6 and KL-6 levels compared to CTD patients (P < 0.05). 18F-FAPI-RGD PET/CT imaging revealed significantly higher bilateral lung SUVmax (P < 0.001) and lower spleen SUVmax (P < 0.05) in CTD-ILD patients. Correlation analysis demonstrated significant positive association between bilateral lung SUVmax and CTD-ILD (r = 0.62, P < 0.001). Multivariate logistic regression adjusted for age, KL-6, and DLCO% identified bilateral lung SUVmax (per 10-unit increase) as an independent predictor of CTD-ILD (OR = 1.459, 95% CI= [1.031–2.065], P = 0.033). Bilateral lung SUVmax exhibited excellent predictive value for ILD (AUC = 0.94, 95% CI= [0.88-1.00], P < 0.001). Multiple linear regression showed KL-6 (β = 0.001, 95%CI [< 0.001, 0.002], P < 0.001) significantly positively influenced bilateral lung SUVmax, while DLCO% (β=-0.031 95%CI [-0.043, -0.020], P < 0.001) exerted significant negative effects.
conclusionsOur findings demonstrate that 18F-FAPI-RGD PET/CT imaging is clinically applicable for CTD-ILD diagnosis. Future studies should explore its value in monitoring disease progression, treatment response assessment, and prognostic evaluation in CTD-ILD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.